Background Many men develop a rising PSA after initial therapy for prostate cancer. While
some of these men will develop a local or metastatic recurrence that warrants further …

Purpose Clinicopathologic features and biochemical recurrence are sensitive, but not
specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a …

Background Despite the availability of numerous genomic predictors of prostate cancer
(PCa) outcome, few comparative studies have been performed. Objective To compare the …

Background Current prostate cancer prognostic models are based on pre-treatment prostate
specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are …

The accurate determination of the risk of cancer recurrence is an important unmet need in
the management of prostate cancer. Patients and physicians must weigh the benefits of …

Purpose For patients with prostate cancer treated by radical prostatectomy, no current
personalized tools predict clinical failure (CF; metastasis and/or androgen-independent …

Accurate prognostication is a prerequisite for accurate therapeutics and management of
prostate cancer because indolent tumors may require no intervention, whereas aggressive …

Background Prostate cancer patients who have a detectable prostate-specific antigen (PSA)
postprostatectomy may harbor pre-existing metastatic disease. To our knowledge, none of …

Background Although chemotherapy for prostate cancer (PCa) can improve patient survival,
some tumours are chemo-resistant. Tumour molecular profiles may help identify the …

Prostate cancer (PC) is one of the most common cancers among men worldwide, and
advanced PCs, such as locally advanced PC (LAPC) and castration-resistant PC (CRPC) …